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Abstract
Objective: This research was aimed to increase the intrinsic dissolution rate (IDR) of
piroxicam with solid dispersion system of piroxicam-betacyclodextrin (SDSPB). This system can
overcome the dissolution problem of piroxicam.
Method: Determination of piroxicam IDR was performed using intrinsic dissolution tester in
100 rpm speed of stir. Free CO2 water was used as solvent. Piroxicam concentration in was
measured using spectrophometer. The piroxicam IDR of SDSPB which was prepared using solvent
method with freeze drying was compared with control (piroxicam alone). Then the interaction of
piroxicam with betacyclodextrin was analyzed using IR spectra.
Result:The IDR of SDSPB and piroxicam pellet are 1.2247 and 0.244 mgcm-2minute-1
respectively. This enhancement was predicted due to inclusion complex and electrostatic interaction
of piroxicam and betacyclodextrin.
Conclusion: The SDSPB can enhance six times fold of piroxicam IDR (p0,05). The
researches purposed to formulate SDSPB tablet and to test its bioavailability are needed to confirms
this IDR enhancement.
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INTRODUCTION
Absorption process in gastrointestinal is
simplified in two steps. Firstly, the dissolution in
gastrointestinal medium and secondly,
permeation trough gastrointestinal membrane to
reach blood in capilar of venaporta hepatica
(Shargel et al, 2005). The poor water solubility
drugs have dissolution problem since the
gastrointestinal medium consist of water
dominantly. Thus to overcome this problem
many pharmaceutical technology including
micronization, formation of complexes (Perrut,
2003) and solid dispersions (Ruan et al, 2005;
Chiou and Riegelman, 1971) are developed. The
solid dispersion system are being the focused of
recent studies (Serajudin, 1999; Sethia and
Squilante, 2003) and several successful products
have been commercialized in pharmaceutical
market.
In solid dispersion system, the very fine
drug particle is dispersed in solid water soluble
carrier, i.e. PVP (polyvinyl pirolidone), PEG
(polyetilen glykol), urea, and cyclodextrin
(Chiou and Riegelman, 1971). This system can
be prepared by melting (fusion) method or
solvent evaporation method (Habib, 2001), or
combination (Chiou and Riegelman, 1971,
Dabbagh and Taghipour, 2007). In fusion
method, the physical mixture of drug and carrier
is heated in high temperature (about 150oC,
depend on their melting point) to reach liquid
state, and then it is cooled quickly to get solid
dispersion. Because of this high temperature,
many drugs degrade (Chiou and Rigelman,
1971). In solvent method the physical mixture of
drug and carrier was dilute in evaporable
semipolar solvent, since the drug is water
insoluble and the carrier is water soluble, and the
solvent must be evaporated in low temperature
(Chiou and Riegelman, 1971). Some solvent are
selected i.e. acetone (Al-Obaidi et al, 2009),
ethanol, and water (Al-Hamidi et al, 2010).
Some approaches are used to concluded
the advantage of solid dispersion system, i.e.
solubility determination (Punitha et al, 2009),
IDR determination (Al-Hamidi et al, 2010),
bioavailability (Tianti et al, 2005), etc. In IDR
determination, the dissolution rate of pellet solid
dispersion is measured in constant surface area,
and IDR is defined as rate of dissolution divided
by surface area. If the IDR is more than 1
mg/cm2/minute, this drug has no problem on
dissolution in gastrointestinal medium.
Generally this drug has more than 1% water
solubility (Shargel and Yu, 1985).
Piroxicam (figure 1) is an NSAIDs which
has poor solubility (23 mg/L). It is a weak acid
with pKa 6,3 (Anonym, 2012). From its water
solubility, it is predicted that piroxicam has
problem on dissolution in gastrointestinal
medium. This research was aimed to overcome
this problem via solid dispersion system using
betacyclodextrin, and to prove this advantage by
measured its IDR.
MATERIAL AND METHOD
Material
The piroxicam was purchased from PT
Indofarma Tbk Bekasi (Dinamite Dipharma
S.p.A). Betacyclodextrin (Sigma) was p.a
degree. Another reagent i.e. sodium hydroxide,
Ammonia, and KBr have p.a degree, produced
by E Merck. Intrinsic Dissolution Tester
designed by Yuwono was produced by T&A
Technique and Supply, Yogyakarta. The
spectrophotometer UV1601PC Shimadzu was
used to determine piroxicam concentration, and
the spectrophotometer FTIR8201PC Shimadzu
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Figure 1. Piroxicam molecular structure
was used to record solid dispersion system IR
spectrum.
Method
Contruction of Calibration Curve
The piroxicam solution (1,1 mg%) was
scanned in 200-400 nm of wave length to get
maximum absorbance wave length (ëmax). The
absorbance of piroxicam solution in various
concentration (0.5; 0.7; 0.9; 1.1; 1.3; and 1.7
mg%) with and without betacyclodextrin in the
same concentration were measured their
absorbance at ëmax. The linear regression of
piroxicam absorbance as the function of
concentration with and without betacyclodetrin
were used to calculate the concentration of
piroxicam released from their pellets in IDR test.
Preparation of Piroxicam-Betacyclodextrin
Solid Dispersion
The piroxicam-Betacyclodextrin Solid
Dispersion System was prepared using solvent
method. Equimol Physical mixture of piroxicam
and betacyclodextrin was dilute in minimum
volume of ammonia solution 25%, the solution
was frezzed. Then the solvent was evaporated
using freeze dryer (Modulyo). Next, the KBr
powder was added to the solid dispersion. This
mixture was pressed on 2 tons weight for 5
minute to get KBr pellet for IR Spectrum
Characterization. The same pellet without KBr
was made to use in IDR test. These pellets have
1,8 cm in diameter and about 200 mg of powder
was needed.
IDR Determination.
The pellet of piroxicam (or solid
dispersion of piroxicam-betacyclodextrin) was
set up in IDR tester. Accurate volume of free
CO2 aquadest (50,0 mL), as solvent, was
maintained its temperature in 37oC using
thermostat. The pellet in IDR tester was brought
in this medium, then the time was started, the
IDR tester was connected to rotor, and it was
rotated 100 rpm. Accurate volume of sample
(3,0 mL) was taken out from medium and the
equal volume of fresh medium was added to
maintain the volume. The sampling time was
scheduled at 2.5, 5, 10, 15, 20, 30, and 45
minutes. The concentration of piroxicam in the
sample was determined using
spectrophotometric method. IDR is defined as
rate of dissolution per surface area. It can be
calculated from the slope of curve of time of
dissolution versus amount of drug dissolved per
surface area (W/A).
RESULT
Calibration Curve of Piroxicam in Water
Piroxicam solution in water has ëmax of
354,8 nm, both with and without
betacyclodextrin. Figure 2 shows calibration
curve of piroxicam in water. These two line are
identical, and have no significant differences
(p>0,05). It can be concluded that
betacyclodextrin do not change the lambda max
and absorbance, so that one of these two
calibration curve can be selected to calculate
piroxicam concentration of sample from IDR test
of solid dispersion system piroxicam-
betacyclodextrin pellet or piroxicam pellet
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Figure 2. Calibration curve of piroxicam with
betacyclodextrin (y=0.4532x – 0.01653) and without
betacyclodextrin (y = 0.4446x + 6.07.10-4).
IDR Determination
Concentration of piroxicam release from
piroxicam pellet and solid dispersion system of
piroxicam-betacyclodextrin pellet are shown in
figure 3. In dissolution test, “sink condition” is
required, it means that the bulk concentration
must be lower than 1/10 of its solubility. This
condition is shown by linear curve between
concentration as the function of time. From
figure 3, it can be concluded that during 30
minutes of dissolution the sink condition is
appear, because of its high R2. Thus the data can
be proceeded to calculate IDR.
The linear equation in figure 4 shows that
solid dispersion system could enhance IDR six
times fold from control. IDR of piroxicam from
solid dispersion is 1.225 mg cm-2 menit-1. Thus
this system showed that piroxicam had no
problem in dissolution in gastrointestinal
medium.
Prediction of Interaction between Piroxicam and
Cyclodextrin
The interaction between piroxicam and
betacyclodextrin was predicted based on
computer software analyzed (HiperChem) and
FTIR spectra. From the molecule structure of
piroxicam and betacyclodextrin, it is predicted
that piroxicam can be entrapped into the hollow
space of betacyclodextrin as shown in figure 5.
This constructure is called inclusion complex,
and since betacyclodextrin has the high water
solubility, the piroxicam entrapped will be
pulled to dissolve.
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Figure 3. Identification of sink condition
Figure 4. The amount of piroxicam dissolved per surface
area. IDR of piroxicam is 0.244 mgcm-2minute-1, IDR of
piroxicam from solid dispersion is 1.225 mgcm-2minute-1
A B
C D
Figure 5. HiperChem prediction of interaction between
piroxicam and betacyclodextrin. A: Piroxicam structure,
B: Betacyclodetrin structure, C: Side view of Piroxicam
(purple) entrapped in betacyclodextrin (green), D:Front
view of Piroxicam (purple) entrapped in betacyclodextrin
(green).
Figure 6. FTIR spectra of piroxicam in KBr pellet
FTIR spectra of piroxicam,
betacyclodextrin, physical mixture of piroxica-
betacyclodextrin, and solid dispersion system of
piroxicam-betacyclodextrin are shown in figure
6, 7, and 8 respectively. Solid dispersion system
of piroxicam-betacyclodextrin has FTIR spectra
differ with its physical mixture. In wavelength
number between 1550 cm-1 to 1000 cm-1, the
solid dispersion system has less intensity than its
physical mixture. This is because of electrostatic
interaction between piroxicam and
betacyclodextrin. The disappearing of S=O
(1184.2) and NH amine (1577.7) in solid
dispersion system indicated that electrostatic
bound was formed between those functional
group. The electron delocalization in piroxicam
formed positive and negative pole as shown in
figure 9. The dispute of electronegativity
between H and O in betacyclodextrin formed
positive partial and negative partial as shown in
figure 9. The positive pole of piroxicam can
interact with the negative partial of
betacyclodextrin, while the negative pole of
piroxicam can interact with positive partial of
betacyclodextrin.
DISCUSION
This study shows that the solid dispersion
system of piroxicam-betacyclodextrin could
enhances the IDR of piroxicam. Since piroxicam
has dissolution as absorption rate limiting step,
the increasing of IDR could overcome the
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Figure 7. FTIR spectra of betacyclodextrin in pellet KBr
Figure 8. Super impose of FTIR spectra of
piroxicam-betacyclodextrin physical mixture of and solid
dispersion system of piroxicam and betacyclodextrin.
Figure 9. Up: Electron delocalization of piroxicam, down: partial polarization of betacyclodextrin monomer
problem of piroxicam absorbtion. It was
predicted that the interaction between
piroxicam-betacyclodextrin in solid dispersion
system will involve the inclusion and
electrostatic complex.
Our result is consistent with the previous
study about overcoming the piroxicam
dissolution problem. Verma et al (2003) could
overcome the dissolution problem of piroxicam
by forming the nicotinamide-piroxicam solid
dispersion using fusion method. Another studies
are listed in table I.
Betacyclodextrin as a carrier for solid
dispersion system has succeeded to enhance the
dissolution of many drugs (Table 2). The hollow
structure is responsible on this ability via
inclusion complex.
CONCLUSION
Solid dispersion system of
piroxicam-betacyclodextrin enhances the IDR of
piroxicam. It is predicted that the interaction
between piroxicam and betacyclodextrin in solid
dispersion system involve inclusion complex
and electrostatic complex. The researches
purposed to formulate SDSPB tablet and to test
its bioavailability are needed to confirms this
IDR enhancement.
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Carrier/complexing agent
Method of solid dispersion
development
References
polyvinylpyrrolidone (PVP)
K-17 PF, PVP K-90
PEG4000, urea
polyethylene glycol 400,
polyvinyl pyrolidone K-30
microcrystalline cellulose,
potato starch
myrj 52, Eudragit® E100,
mannitol
Polyvinylpyrrolidone
Solvent method
fusion and solvent methods
Solvent method
Solvent method
Solvent method, precipitation
method
Antisolvent precipitation, spray
drying techniques
Tantishaiyakul et al, 1999
Pan et al, 2000
Patel et al, 2003
Charumanee et al, 2004
Valizadeh et al, 2007
Wu et al, 2008
Table I. Some effort to overcome piroxicam dissolution problem
Drugs
Method of solid dispersion
development
references
Ketorolac
Ketoconazole
Domperidone
Fenbendazole
Ibuprofen
Solvent method
Solvent method
Solvent method
Solvent method
Solvent method
Nagarsenker et al, 2000
Balata et al, 2010
Swami, et al, 2010
Nagesh et al, 2011
Kumar et al, 2012
Table II. Usage of betacyclodextrin to enhance dissolution of poor solubility drugs
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